Co-crystals incorporate pharmaceutically acceptable guest molecules into a crystal lattice along with the active pharmaceutical ingredience (API). polymorphism in multi-component crystals is gaining interest in the recent times in the context of pharmaceutical co-crystals.the physical and chemical property improvements through pharmaceutical co-crystals draw closer the fields of crystal engineering and pharmaceutical science. The aim of this review is to present an extensive overview of the co-crystalization methods, focusing in the specifics of each technique, it’s advantages and disadvantages.co-crystals can be prepared from two molecule of any shape or size having complementary hydrogen bond functionalities. Amorphous phases generated by pharmaceutical processes lead to co-crystal formation during cogrinding and storage. Physiochemical properties of drugs can tailored by various approaches such as salt formation, micronization, solid dispertion, amorphous drugs encapsulation.co-crystalization of drug and coformercan affect the crystals packing, tabletability and compaction, which are important parameters during preformulation study. Poor aqueous solubility and low oral bioavailability of an active pharmaceutical ingredient are the major constrints during the development of new product.
Cite this article:
Chameli S. Daingade, Bhavna U. Jain, Manish Kondawar. Pharmaceutical Co-Crystalization: A Review. Res. J. Pharma. Dosage Forms and Tech.2019; 11(2):143-146. doi: 10.5958/0975-4377.2019.00024.7
Chameli S. Daingade, Bhavna U. Jain, Manish Kondawar. Pharmaceutical Co-Crystalization: A Review. Res. J. Pharma. Dosage Forms and Tech.2019; 11(2):143-146. doi: 10.5958/0975-4377.2019.00024.7 Available on: https://rjpdft.com/AbstractView.aspx?PID=2019-11-2-15